16 September 2025 in European Journal of Radiology
14 December 2022 in Cancer Prevention Research
The incidence of breast cancer among premenopausal women has been increasing rapidly in recent decades in East Asia. This case–control study investigated whether estrogen-DNA adducts were associated with breast cancer risk in Taiwan. The control group (n = 146) comprised healthy female volunteers and women with non-proliferative breast disease. The case group (n = 221) comprised women either with proliferative benign breast disease or breast cancer. The ratios of estrogen-DNA adducts to their respective metabolites and conjugates in plasma were analyzed using ultraperformance LC/MS-MS. The SNPs of CYP1A1, CYP1B1, and COMT were genotyped. Logistic regression model was used to compare the estrogen-DNA adduct ratios between the two groups. The estrogen-DNA adduct ratio in the case group was significantly higher than that in the control group (median ratio: 58.52 vs. 29.36, P = 0.004). A multiple logistic regression model demonstrated that a unit increase in the natural log of the estrogen-DNA adduct ratio in premenopausal women was a significant predictor of breast cancer risk, with an estimated hazard ratio of 1.718 (1.444−2.046, P < 0.001). However, the CYP1A1, CYP1B1, and COMT SNPs were not associated with the estrogen-DNA adduct ratios. In conclusion, plasma estrogen-DNA adduct ratio was associated with the presence of breast cancer or proliferating benign breast disease in premenopausal women in Taiwan. Prevention Relevance: This study provides evidence that endogenous estrogen-induced genotoxicity may contribute to the carcinogenesis of breast cancer in premenopausal Asian women. This work could have important preventive implication for the emerging disease in East Asia.
1 July 2025 in Communications Medicine
Background Conventional histopathological examination for breast core needle biopsy diagnosis is time-consuming and labor-intensive, leading to delayed medical treatments and increased psychological burden for patients. A rapid and reliable diagnostic method is needed to assist routine pathological diagnosis. Methods We developed a miniature mass spectrometry platform coupled with paper spray ionization (MiniMaP) for rapid breast cancer diagnosis. This platform enables direct molecular analysis of biopsy samples without sample preparation. A machine learning model was trained to differentiate benign and malignant samples based on molecular profiles. The platform’s performance was further evaluated in a 22-month multicenter validation study. Results Here we show that the machine learning model trained on molecular profiles achieves 88% accuracy in distinguishing breast cancer from benign samples. The model identifies 60 molecular features as potential biomarkers. Additionally, MiniMaP is implemented for on-site analysis in a hospital setting, enabling breast cancer diagnosis within 5 min. The platform maintains consistent accuracy (84%) across 540 biopsy samples over the 22-month validation period. Conclusions Our results demonstrate that the MiniMaP platform enables rapid breast cancer diagnosis and maintains consistent performance in long-term multicenter validation. It holds promise for assisting clinical breast cancer diagnosis by providing instant diagnostic reports to support timely medical decisions and improve medical care.